Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-24-008797

Director bought 444,444 shares at $18.00 ($7,999,992)

  • Director acquired 2,582,884 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
GORDON CARL L Director 2024-01-30 Conversion +821,827 821,827 I: show line 1 in the form
GORDON CARL L Director 2024-01-30 Conversion +821,827 821,827 I: show line 2 in the form
GORDON CARL L Director 2024-01-30 Conversion +469,615 1,291,442 I: show line 3 in the form
GORDON CARL L Director 2024-01-30 Conversion +469,615 1,291,442 I: show line 4 in the form
GORDON CARL L Director 2024-01-30 Purchase +222,222 $18.00 $3,999,996 1,513,664 I: show line 5 in the form
GORDON CARL L Director 2024-01-30 Purchase +222,222 $18.00 $3,999,996 1,513,664 I: show line 6 in the form
Open-market purchases · 444,444 sh · avg $18.00 · $7,999,992

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
GORDON CARL L Director 2024-01-30 Conversion · Series A Preferred Stock −821,827 0 I: show line 7 in the form
GORDON CARL L Director 2024-01-30 Conversion · Series A Preferred Stock −821,827 0 I: show line 8 in the form
GORDON CARL L Director 2024-01-30 Conversion · Series B Preferred Stock −469,615 0 I: show line 9 in the form
GORDON CARL L Director 2024-01-30 Conversion · Series B Preferred Stock −469,615 0 I: show line 10 in the form
Loading xslF345X05/tm244611-3_4seq1.xml…